Video-assisted thoracoscopic surgery lobectomy for stage I lung cancer

The literature shows that, in the hands of experienced thoracoscopic surgeons, VL is a safe operation that offers patients at least comparable complication and survival rates compared with lobectomy by thoracotomy. VL can be performed safely with proven advantages over conventional thoracotomy for lobectomy: smaller incisions, decreased postoperative pain, decreased LOS, decreased chest tube output and duration, decreased blood loss, better preservation of pulmonary function, and earlier return to normal activities. These results are obtained without sacrificing the oncologic principles of thoracic surgery, and, in fact, the evidence in the literature is mounting that VATS may offer reduced rates of complications and better survival.     

Video-assisted thoracoscopic surgery lobectomy for lung carcinoma

Video-assisted thoracoscopic surgery (VATS) has been utilized worldwide for the treatment of various types of thoracic disease, in particular for lung carcinoma. The following criteria are accepted as the operative indications for VATS lobectomy: i) clinical T1N1M0: ii) tumor located in the peripheral zone; and iii) non-small cell carcinoma. Videoscopic surgery has the merit of being less invasive, resulting in a low level of postoperative chest pain, short incisional scar, and short duration of hospital stay. Right-side upper mediastinal lymph node dissection is easy under the thoracoscope, although compared with standard thoracotomy it is not always possible to perform complete level II dissection on the left, because of the difficult approach to lymph nodess No. 3 and No. 4 under the aortic arch via the thoracoscope. The postoperative 5-year survival rate after VATS lobectomy is superior to that after standard thoracotomy. It is expected that the indications for VATS will be expanded to include T2 or N1 disease as thorascopic instruments and techniques improve.     

微小N2非小细胞肺癌胸腔镜肺叶切除与同期开胸手术对照研究

目的 研究分析临床分期Ⅰ期接受胸腔镜肺叶切除,术中意外发现微小纵隔淋巴结转移(N2)的非小细胞肺癌患者的近、远期预后.方法 回顾性分析2004年1月至2007年12月术前诊断为早期非小细胞肺癌(cT1-2N0M0,Ⅰ期),而术中或术后意外发现微小纵隔淋巴结转移(pT1-2N2M0,Ⅲa期)患者263例的临床资料.全部患者接受肺叶切除术+系统淋巴结清扫根治性治疗.其中接受胸腔镜肺叶切除术63例(腔镜组),男性37例,女性26例,平均年龄(58±11)岁.同期接受开胸肺叶切除术治疗的为200例(开胸组),男性132例,女性68例,平均年龄(59±11)岁.对比上述两组患者的临床特征及近、远期预后.结果 全部263例患者平均生存时间(34.9±1.2)个月,中位生存时间31个月.腔镜组平均生存时间(40.3±2.2)个月,中位生存时间37个月;开胸组平均生存时间(33.1±1.3)个月,中位生存时间29个月.全部患者1、2、3年生存率为92.0%、57.4%、29.3%,腔镜组1、2、3年生存率为92.1%、82.5%、41.3%,开胸组1、2、3年生存率为92.0%、49.5%、25.5%,两组间差异有统计学意义(x2=5.58,P=0.018).结论 VATS肺叶切除治疗微小N2非小细胞肺癌是安全、有效的.患者经过术前严格的评估,手术中出现意料之外的纵隔淋巴结转移,通过系统的淋巴结清扫后没有必要中转开胸完成手术.

Abstract：

Objective To assess early and late outcomes of patients with minimal mediastinal lymph nodes metastasis N2 non-small cell lung cancer disease unexpectedly detected during the operation, who underwent video-assisted thoracic surgery lobectomy for clinical stage I. Methods This study retrospectively reviewed and analyzed the medical records of 263 patients underwent surgery between January 2004 and December 2007, who were diagnosed as having early-stage non-small cell lung cancer (clinical stage was cT1-2N0M0, stage Ⅰ) before the surgery, but were found to have mini mediastinal lymph nodes metastasis disease (clinical stage was pTI-2N2M0, stage Ⅲa) unexpectedly detected during the operation and after the operation. All patients underwent lobectomy and systematic lymph nodes dissection as radical treatments. Among them, 63 patients underwent video-assisted thoracic surgery (VATS) lobectomy,including 37 male patients (58. 7%) with a mean age of (58 ± 11) years old. Two hundred patients underwent open thoracotomy lobectomy, including 132 male patients (66%) with a mean age of (59 ± 11) years old. To compare and analyze clinical features, early and late outcomes of patients in these two groups.Results A total of 263 patients with an average survival time (34. 9 ± 1.2) months (median 31 months),63 cases in VATS lobectomy group with an average survival time (40. 3± 2. 2) months (median 37 months), 200 cases in open pulmonary lobectomy group with an average survival time (33.1 ±1.3)months (median 29 months). The 1 -, 2-, 3-year over survival rate of all the patients was 92.0%, 57.4%,29. 3%. The 1-, 2-, 3-year survival rate of patients in VATS lobectomy group was 92. 1%, 82. 5%,41.3%. The 1,2,3 year survival rate of patients in thoracotomy lobectomy group was 92. 0%, 49. 5%,25.5%. There was significant difference between the two groups in this factor (x2 =5.58, P =0.018).     

Video-assisted thoracic surgery lobectomy reduces the morbidity after surgery for stage I non-small cell lung cancer

Objective: We conducted this study to evaluate the surgical invasiveness and the safety of video-assisted thoracic surgery lobectomy for stage I lung cancer. Methods: Video-assisted thoracic surgery lobectomies were performed on 43 patients with clinical stage IA non-small cell lung cancer. We compared the surgical invasiveness parameters with 42 patients who underwent lobectomy by conventional thoracotomy. Results: Intraoperative blood loss was significantly less than that in the conventional thoracotomy group (151±149 vs. 362±321 g, p<0.01). Chest tube duration (3.0±2.1 vs. 3.9±1.9 days) was significantly shorter than those in the conventional thoracotomy group (p<0.05). The visual analog scale which was evaluated as postoperative pain level on postoperative day 7, maximum white blood count and C-reactive protein level were significantly lower than those in the conventional thoracotomy group (p<0.05). The morbidity rate was significantly lower than that in the conventional thoracotomy group (25.6% vs. 47.6%, p<0.05). Sputum retention and arrhythmia were significantly less frequent than in the conventional thoracotomy group (p<0.05). We experienced no operative deaths in both groups. Conclusion: We conclude that video-assisted thoracic surgery lobectomy for stage I non-small cell lung cancer patients is a less invasive and safer procedure with a lower morbidity rate compared with lobectomy by thoracotomy.     

Effects of vessel interruption sequence during thoracoscopic lobectomy for non-small cell lung cancer

Objective

This study aimed to determine if the vessel interruption sequence during thoracoscopic lobectomy affects disease recurrence.

Methods

We retrospectively analyzed 187 consecutive patients who underwent video-assisted thoracoscopic surgery lobectomy with curative intent for non-small cell lung cancer between January 2007 and December 2013. Their clinicopathological, operative, and postoperative data were compared. Patients with minimally invasive adenocarcinoma were excluded.

Results

A total of 104 patients underwent total venous interruption before interruption of any artery branch (V-first), while 83 patients underwent some artery interruption first (non-V-first). Clinicopathological characteristic distributions were similar between both groups except for the resected lobe. Seven of 104 patients in the V-first group and 15 of 83 patients in the non-V-first group experienced disease recurrences. Among the 187 patients who underwent thoracoscopic lobectomy, overall survival tended to be longer in the V-first group than in the non-V-first group (P?=?0.080). Furthermore, disease-free survival was significantly longer in the V-first group than in the non-V-first group (P?=?0.019), particularly in stage I patients (P?=?0.047). Multivariate analysis showed that vessel interruption sequence was a significant prognostic factor for poor disease-free survival, after adjusting for pathological stage and histology (hazard ratio 2.127; 95% confidence interval 1.009–4.481). There was no significant difference in intraoperative blood loss between both groups.

Conclusions

Interrupting the pulmonary vein first may be associated with improved disease-free survival in patients undergoing thoracoscopic lobectomy for non-small cell lung cancer.

     

Video-assisted thoracic surgery lobectomy for stage I lung cancer

BACKGROUND: The technique, safety, and oncologic efficacy of video-assisted thoracic surgery (VATS) lobectomy are controversial. Issues include operative time, lymph node yield, conversion to thoracotomy, resource utilization, recurrence, complications, and survival. METHODS: From January 1995 to December 2001, 179 patients underwent VATS lobectomy for preoperative stage I lung cancer (T1N0, 118 patients; T2N0, 61 patients). Mean age was 64.34 years (range, 38 to 87); 91 were female and 88 were male. Contraindications to VATS lobectomy included any suggestion of hilar, endobronchial, or central lesions. Video-assisted thoracic surgery lobectomy was performed using three ports, partial anatomic hilar dissection, and mediastinal node dissection. RESULTS: Distribution of lobectomies was as follows: left upper lobe, 50 patients; left lower lobe, 27 patients; right upper lobe, 33 patients; right upper and right middle lobe, 29 patients; right middle lobe, 9 patients; right lower lobe, 30 patients; right middle lobe and right lower lobe, 1 patient. Mean operative time was 75 +/- 6 minutes. Mean lymph node yield was 11 +/- 5 nodes. Pathologic upstaging was noted in 14 of the 179 patients (7.8%). Mean hospitalization was 4.1 days (range, 2 days to 4 months). There were no conversions to thoracotomy and there was 1 death (1 of 179, 0.05%). Complications included air leak in 24 of 179 (13.4%), subcutaneous emphysema in 4 of 179 (2.2%), pneumonia in 10 of 179 (5.6%), wound infection in 5 of 179 (2.8%), respiratory failure in 3 of 179 (1.7%), pulmonary embolism in 2 of 179 (1.1%), and myocardial infarction in 1 of 179 (0.5%). At a mean follow-up of 37 months, local recurrence rate was 0.013 per person per year. Actuarial recurrence-free survival was 88% and 85% at 36 and 60 months respectively. CONCLUSIONS: For carefully selected patients VATS lobectomy for early stage lung cancer is a safe and effective strategy. Long-term follow-up is required to fully evaluate recurrence and survival.     

Video-assisted thoracoscopic surgery for lung cancer: current indications

Recently, video-assisted thoracoscopic surgery (VATS) has been widely applied in lung cancer surgery in Japan, although there is no consensus on the definition of VATS and its standard techniques. VATS lobectomy may result in long-term survival rates as high as after standard thoracotomy and is becoming an optional treatment for stage IA lung cancer. It is still not a standard treatment because of the problems of safety and oncologic radicality. However, as long as the safety and radicality are ensured by the tumor type, patient risk factors, and the expertise of the surgeon, less-invasive techniques like VATS should be performed.     

Video-assisted thoracoscopic surgery node dissection for lung cancer treatment

Purpose

Mediastinal node dissection (MND) is an integral component of the surgical treatment for non-small cell lung cancer (NSCLC). Although video-assisted thoracoscopic surgery (VATS) has been used increasingly for lung cancer treatment, the accuracy of by VATS MND still remains controversial. We reviewed the surgical results of VATS MND for NSCLC.

Methods

A systematic review of literature was performed, and articles that fully described the surgical procedure, devices, and results of VATS MND were selected to compare the efficacy of MND by VATS and thoracotomy.

Results

Various techniques and equipments have been shown to perform adequate MND, but there is an argument as to the method of estimation of the accuracy of MND. Most of the recent studies showed that the nodal upstaging and number of dissected nodes are significantly lower by VATS than after thoracotomy. Oppositely, some studies showed VATS noninferiority in these issues. Complications such as chylothorax, pleural effusion, bleeding, and nerve damage were similar in both groups.

Conclusions

Although ND by VATS remains controversial, VATS MND is becoming easier and more feasible owing to the development of more advanced endoscopic cameras and equipments. We should learn further to become more adept at performing adequate ND by VATS.

     

Video-assisted thoracoscopic lobectomy vs. conventional lobectomy via open thoracotomy in patients with clinical stage IA non-small cell lung carcinoma

The aim of this study was to evaluate our personal experience with video-assisted thoracoscopic lobectomy and compare survival between this procedure and conventional lobectomy via open thoracotomy in patients with clinical stage IA non-small cell lung carcinoma. Between May 1997 and December 2004, 140 patients with clinical stage IA non-small cell lung carcinoma had either VATS lobectomy (VATS group, 84 patients) or standard lobectomy via open thoracotomy (open group, 56 patients) performed in our hospital. We compared overall survival, disease-free survival and recurrence between the two groups. The overall survival rate five years after surgery was 72% in the open group and 82% in the VATS group. There were no significant differences in the overall survival rate between the two groups. The disease-free survival rate five years after surgery was 68% in the open group and 80% in the VATS group. There were no significant differences in the disease-free survival rate between the two groups. Five patients in the open group developed distant recurrence, whereas one patient developed regional recurrence. In the VATS group six patients developed distant recurrence, whereas one patient developed regional recurrence. We consider VATS lobectomy to be one of the therapeutic options in patients with clinical stage IA non-small cell lung carcinoma.     

Video-assisted thoracoscopic surgery for right middle lobectomy in children

This case-control study was designed to evaluate the potential advantages and disadvantages of video-assisted thoracoscopic surgery for right middle lobectomy in children. Ten children (6.1±3.0 yr, mean±SD) who underwent right middle lobectomy under videoscopy were compared with 10 controls matched for age (6.8±3.5 yr) and operated by thoracotomy (muscle-sparing technique) during the same period by the same surgeon. Operating time was significantly longer in the videoscopy group than in the thoracotomy group (146±28 mn vs 100±27 mn, P<0.001). Minimum oxygen saturation values were significantly higher in the videoscopy group whereas oxygen requirements did not differ between groups. Incidence of postoperative respiratory complications (mainly atelectasis) was similar in the two groups. No difference in postoperative analgesic requirements in the postoperative period was demonstrated. No real benefit or disadvantage of videoscopy over standard thoracotomy could be observed in this retrospective case-control study.     

Sleeve lobectomy for non-small cell lung cancer

Sleeve lobectomy is a procedure in which the involved lobe with part of the main stembronchus is removed. The remaining lobe (s) is reimplanted on the main stembronchus. This procedure is indicated for central tumors of the lung as an alternative to pneumonectomy. It is the aim of this study to describe the technique of sleeve lobectomy and to analyse the early postoperative results and late results (survival-recurrence) after sleeve lobectomy for non-small-cell lung cancer. MATERIAL AND METHODS: Between 1985 and 1999, 77 sleeve lobectomies for bronchogenic carcinoma were performed at the University hospitals Leuven. The most common performed sleeve lobectomy is the right upper lobe sleeve lobectomy (67.5%). In 6 patients a combined sleeve resection of the pulmonary artery was performed. The operative mortality was 3.9%. Two patients developed a broncho-pleural fistula. The five-year survival rate was 45.6%. In 5 patients, an anastomotic suture developed which required a completion pneumonectomy in 2. Thirteen patients developed local tumor recurrence. CONCLUSION: We conclude that sleeve lobectomy can be performed with an acceptable mortality and morbidity. Long term survival rate and recurrence rate are as good as after pneumonectomy. The operative mortality is lower when compared to pneumonectomy, exercise tolerance and quality of life are much better after sleeve lobectomy compared to pneumonectomy. For central tumours we believe that sleeve resection is the procedure of choice.     

Video-assisted thoracoscopic lobectomy with bronchoplasty for lung cancer: tip regarding bronchial anastomosis

No study has discussed the application of video-assisted thoracoscopic surgery (VATS) to bronchoplasty or the handling of a needle and forceps in a bronchial anastomosis. We use the following steps for bronchial anastomosis: Insert the needle and forceps vertical to the bronchial wall, move them in such way as to scoop something up, rotate and turn around, repeat the second step, and pull from the bronchial wall along the curvature of the needle. Handling the needle forceps along the curvature of the needle is critically important.     

胸腔镜肺叶切除术治疗早期肺癌的学习曲线

目的 通过评估胸腔镜肺叶切除术治疗早期肺癌不同阶段的手术效果,探讨胸腔镜肺叶切除术的学习曲线.方法 回顾性分析2006年9月至2008年6月由同一手术组连续完成的60例全胸腔镜下肺叶切除加纵隔淋巴结清扫术治疗早期肺癌的病例资料.按手术先后依次分为4组(A、B、C、D),每组15例,比较各组手术时间、术中出血量、纵隔淋巴结清扫站数及个数、中转开胸率、术后并发症、术后胸管引流时间以及术后住院天数,分析不同阶段的手术效果.结果 各组病例在年龄、性别、肿瘤大小、病理分期以及手术方式等方面差异无统计学意义(P>0.05).A组手术时间(228.0±55.6)min明显长于C组(155.0±33.6)min或D组(152.7±27.4)min(P<0.001),B组手术时间(200.3±67.1)min亦明显长于C组或D组(P<0.05),而C、D两组之间差异无统计学意义(P=0.896);在术中出血量方面,A组(283.3±111.2)ml明显多于C组(156.7±86.3)ml或D组(143.3±67.8)ml(P<0.01),B组(286.7±188.4)ml亦明显多于C组或D组(P<0.01),C、D两组之间差异无统计学意义(P=0.767);各组淋巴结清扫数量、中转开胸率、术后并发症、术后胸管引流时间以及术后住院天数比较,差异均无统计学意义(P>0.05).结论 胸腔镜肺叶切除术的学习曲线大约为30例.     

电视胸腔镜手术治疗转移性肺肿瘤

目的探讨肺转移瘤电视胸腔镜手术(video-assisted thoracoscopic surgery ,VATS)的治疗效果. 方法回顾分析31例VATS治疗肺转移瘤的临床资料,其中肺叶切除2例,肺叶切除联合转移瘤摘除1例,肺叶切除联合胸壁转移瘤切除1例,肺段切除 2例,肺楔形切除 20例,肺楔形切除联合转移瘤摘除5例. 结果无住院死亡,术后呼吸功能不全1例,肺部感染2例、持续肺疱漏气2例、胸腔积液3例,经抗生素治疗、持续胸腔闭引流后治愈.1例肝癌肺转移术后2个月发现腰椎骨转移,转骨科行手术治疗.1年生存率71.0%(22/31),3年生存率38.7%(12/31). 结论 VATS治疗有手术指征的肺转移瘤可行、安全.     

电视胸腔镜下治疗肺叶切除术后支气管胸膜瘘

本文报道 2例肺癌患者行肺叶切除分别于术后第 4、7天出现支气管胸膜瘘。再次手术经VATS直接以无损伤编织线缝合封闭瘘口 ,外用医用合成胶或生物蛋白胶。 2例支气管膜瘘均治愈出院。     

Comparison of costs for video-assisted thoracic surgery lobectomy and open lobectomy for non-small cell lung cancer

Background  

To promote the broad use of video-assisted thoracic surgery (VATS) for lobectomy (VATSL) in the management of lung cancer, it should be proved cost-effective, especially in the current cost-sensitive climate. This study evaluated and compared the costs of VATSL and open lobectomy (OL) and analyzed how the surgeon’s experience level with VATSL affected the cost.     

单操作孔完全胸腔镜非小细胞肺癌根治术

目的总结单操作孔完全胸腔镜手术行非小细胞肺癌根治术中的经验。方法行单操作孔全胸腔镜下肺癌根治术60例,右上肺叶切除19例,右肺中叶切除4例,右下肺叶切除20例。左上肺叶切除12例,左肺下叶切除5例。胸腔镜观察孔取腋中线第7肋间,做2 cm左右切口,操作孔根据病灶部位选择第4或5肋间取腋前线至腋中线间,切口长约4~5 cm,经单操作孔完成肺癌根治术。结果全组患者手术顺利,无围手术期死亡患者,无严重术后并发症。清扫淋巴结平均(12.5±2.1)枚。平均手术时间(185.2±10.4)分钟。术中出血平均(150.5±30.6)ml。胸腔引流管拔除时间平均(3.5±1.5)天。术后住院时间平均(5.5±1.2)天。结论和传统腔镜手术比较,单操作孔减少了背部伤口,进一步减小创伤。单操作孔完全胸腔镜手术常规胸腔镜器械可完成,不需增加特殊器械。患者选择恰当并且按正确顺序操作,是单操作孔胸腔镜手术成功的重要保证。